Global $43 Billion Generic Injectables Market 2017-2022 - Key Players are Hospira (Pfizer), Fresenius Kabi, Hikma, Sandoz (Novartis), Sagent, Sanofi and Baxter
DUBLIN, August 29, 2017 /PRNewswire/ --
The "Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report has been added to Research and Markets' offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The global generic injectables market reached a value of more than US$ 43 Billion in 2016, exhibiting a CAGR of around 9% during 2009-2016.
Unlike branded drug manufacturers who spend millions of dollars on R&D and marketing, generic drug manufacturers do not require such investments. Moreover, the number of competitors in the generic injectables market is lower as compared to oral generics, resulting in limited price erosion and significantly higher profit margins.
Owing to the advantages offered by generic injectables, governments in various countries are supporting their manufacture. Additionally, an increase in drug shortages, especially in the US, along with patent expiry of a number of blockbuster drugs, aging population and rising prevalence of chronic as well as lifestyle diseases represent some of the other factors driving the growth of the market. According to
The report also provides a comprehensive analysis for setting up a generic injectables manufacturing plant. The study analyses the processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global generic injectables industry in any manner.
The report has also analysed the competitive landscape of the market with some of the key players being Hospira (Pfizer), Fresenius Kabi, Hikma, Sandoz (Novartis), Sagent, Sanofi and Baxter.
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Generic Drug Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Region
5.4 Market Forecast
5.5 Major Players
6 Global Generic Drug Delivery Market
6.1 Oral
6.2 Injectables
6.3 Dermal/Topical
6.4 Inhalers
7 Global Generic Injectables Market
7.1 Market Overview
7.2 Market Performance
7.3 Market Breakup by Region
7.4 Market Breakup by Therapeutic Area
7.5 Market Breakup by Distribution Channel
7.6 Market Forecast
8 Global Generic Injectables Market: Performance of Key Regions
9 Market by Therapeutic Area
9.1 Oncology
9.2 Anaesthesia
9.3 Anti-infectives
9.4 Parenteral Nutrition
9.5 Cardiovascular
10 Market by Distribution Channel
10.1 Hospitals
10.2 Retail Pharmacy Stores
11 Global Generic Injectable Market: Competitive Landscape
11.1 Competitive Structure
11.2 Market Breakup by Key Players
12 Generic Injectable Manufacturing Process
12.1 Product Overview
12.2 Detailed Process Flow (Injectable)
12.3 Various Types of Unit Operations Involved
12.4 Mass Balance and Raw Material Requirements
13 Project Details, Requirements and Costs Involved
13.1 Land Requirements and Expenditures
13.2 Construction Requirements and Expenditures
13.3 Plant Machinery
13.4 Machinery Pictures
13.5 Raw Material Requirements and Expenditures
13.6 Packaging Requirements and Expenditures
13.7 Transportation Requirements and Expenditures
13.8 Utility Requirements and Expenditures
13.9 Manpower Requirements and Expenditures
13.10 Other Capital Investments
14 Loans and Financial Assistance
15 Project Economics
15.1 Capital Cost of the Project
15.2 Techno-Economic Parameters
15.3 Product Pricing and Margins Across Various Levels of the Supply Chain
15.4 Taxation and Depreciation
15.5 Income Projections
15.6 Expenditure Projections
15.7 Financial Analysis
15.8 Profit Analysis
16 Key Player Profiles
16.1 Hospira (Pfizer)
16.2 Fresenius Kabi
16.3 Hikma
16.4 Sandoz (Novartis)
16.5 Sagent
16.6 Sanofi
16.7 Baxter
For more information about this report visit https://www.researchandmarkets.com/research/78txmq/generic
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
